Robert Etherington
CEO, President & DirectorMr. Robert Etherington, also known as Rob, MBA, serves as Chief Executive officer, President and Director at Clene Nanomedicine, Inc. He serves as President, Chief Executive Officer and Director at Clene Inc. since April 2013. He serves as the Chief Executive Officer and President of Clene Nanomedicine Inc since April 2013. Mr. Etheringtonserves as Vice President of Eastern Business Unit at Veletri, where is responsible for the management of Actelion's field sales colleagues in the business unit and for ensuring attainment. From June 2016 to 2023, Mr. Etherington served on the Board of BioUtah, an independent trade association serving the life science industry in the State of Utah, including a term as Vice-Chair, Chairman and Executive Chair. Mr. Etherington has also been a Director of Corsair LLC, a privately held biotechnology company, since March 2018. He has held a variety of roles over his many years in the pharmaceutical industry. Mr. Etherington served as Senior Vice President of Commercial at Actelion Pharmaceuticals US, Inc. He served as Vice President of Eastern Business Unit and Senior Vice President of Sales & Marketing at Actelion Pharmaceuticals U.S., Inc. Mr. Etherington joined Parke-Davis, a division of the Warner-Lambert company, in 1992. After initial field sales responsibilities, he served positions of increasing responsibility in marketing. Since 1994, He served as regional product Manager of Parke-Davis, he was responsible for PD's hypertensive, anti-arrhythmic and lipid franchise. After regional responsibility for pre-launch Lipitor activities (1996), he transitioned to Rezulin (diabetes) for its launch. In 1998, he joined the worldwide cardiovascular team as one of the Lipitor team leaders. He also served on the development team for PD's vascular gene therapy (veg-F) program and was one of Warner-Lambert/Pfizer's Global Leader Associates. He left Pfizer in 2000 to be the founding Director of Marketing during the IPO year of Swiss-based, Actelion Pharmaceuticals, focused in cardiopulmonary disease. At Actelion, Mr. Etherington served first as Vice President of Marketing, responsible for the Tracleer (bosentan) global brand plan and launch and promotion of Tracleer. Mr. Etherington also served as the Area 2 (North American and Asia-Pacific rim) commercialization leader for life cycle development, then the worldwide Team Leader at Veletri (tezosentan; for Acute Heart Failure) until the cessation of its development. Mr. Etherington obtained a bachelor’s degree of art from Brigham Young University in August 1990. He received his master’s degree of business administration from Brigham Young University in April 1992, majored in business with a pharmaceutical healthcare emphasis. Mr. Etherington also completed the alumnus-granting General Management Program in Harvard University in June 2011. He holds B.S. in business with a pharmaceutical healthcare emphasis from Brigham Young University.
Positions
- Company NameClene Inc.Stock CodeCLNNPositionCEO, President & DirectorColleagues
- DJDavid J. MatlinIndependent Chairman of the Board
- MRMorgan R. BrownChief Financial Officer
- MGMark G. MortensonChief Science Officer
- JMJerry MiragliaGeneral Counsel & Corporate Secretary
- MAMary Anne McneilHead of Human Resources
- SJShalom JacobovitzIndependent Director
- AHAlison H. MoscaIndependent Director
- RNReed Neil WilcoxIndependent Director
